In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census
暂无分享,去创建一个
[1] E. Appella,et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.
[2] N. Rosen,et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[3] Alessandro Sette,et al. Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1 , 2001, The Journal of Immunology.
[4] T. Tuttle. Oncogene products represent potential targets of tumor vaccines , 1996, Cancer Immunology, Immunotherapy.
[5] P. Darcy,et al. Autoimmunity associated with immunotherapy of cancer. , 2011, Blood.
[6] Sorin Istrail,et al. Comparative immunopeptidomics of humans and their pathogens. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] Avital Lev,et al. Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen 1 , 2003, The Journal of Immunology.
[8] E. Thorsby,et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation , 1995, The Lancet.
[9] P. Coulie,et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. , 2001, Cancer research.
[10] P. Romero,et al. Expression Hierarchy of T Cell Epitopes from Melanoma Differentiation Antigens: Unexpected High Level Presentation of Tyrosinase-HLA-A2 Complexes Revealed by Peptide-Specific, MHC-Restricted, TCR-Like Antibodies1 , 2009, The Journal of Immunology.
[11] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[12] N. Rosen,et al. B-Raf requires the Hsp 90 chaperone for stability and is degraded in response to Hsp 90 inhibitors , 2005 .
[13] T. Vincent,et al. Lessons from applied ecology: cancer control using an evolutionary double bind. , 2009, Cancer research.
[14] S. Groshen,et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Morten Nielsen,et al. Prediction of epitopes using neural network based methods. , 2011, Journal of immunological methods.
[16] K. Döhner,et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. , 2012, Blood.
[17] E. Thorsby,et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study , 1996, International journal of cancer.
[18] F. Marincola,et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers , 2008, Cancer Immunology, Immunotherapy.
[19] D. Taub,et al. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. , 1995, Journal of the National Cancer Institute.
[20] K. Kinzler,et al. Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.
[21] S. Korn,et al. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. , 2007, Lung cancer.
[22] E. Klechevsky,et al. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. , 2008, Cancer research.
[23] E. Angevin,et al. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. , 1999, Journal of immunology.
[24] S. H. van der Burg,et al. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.
[25] E. Thorsby,et al. Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. , 1996, British Journal of Cancer.
[26] Morten Nielsen,et al. State of the art and challenges in sequence based T-cell epitope prediction , 2010, Immunome research.
[27] P. Coulie,et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. , 2011, Cancer research.
[28] René L Warren,et al. A census of predicted mutational epitopes suitable for immunologic cancer control. , 2010, Human immunology.
[29] Harris Papadopoulos,et al. Machine learning competition in immunology - Prediction of HLA class I binding peptides. , 2011, Journal of immunological methods.
[30] D. Busch,et al. MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. , 1998, Journal of immunology.
[31] J. Castle,et al. Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.
[32] E. Mardis,et al. Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.